You are here

Timothy Lewis


Lewis TA, Sykes DB, Law JM, et al. Development of ML390:  A human DHODH inhibitor that induces differentiation in acute myeloid leukemia. ACS Med Chem Lett. 2016;7(12):1112-1117.

de Waal L, Lewis TA, Rees MG, et al. Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016;12(2):102-8.

Sykes DB, Kfoury YS, Mercier FE, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167(1):171-186.e15.

Timothy Lewis, Ph.D.

Timothy Lewis is a senior research scientist working under the direction of Robert Hilgraf in the Chemical Biology Program of the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. The main emphasis of his research has been working with high-throughput screening hits, optimizing them to improve potency and pharmacokinetic properties. As many of these hits have come from phenotypic screens, analogs are often required for target ID efforts. 

Prior to joining the Broad Institute in 2005 as head of synthetic chemistry, Lewis worked as a senior scientist at UCB Pharma. Lewis holds a Ph.D. in organic chemistry from the University of California, Berkeley, and an A.B. in chemistry and math from Wabash College in Crawfordsville, Indiana.

Contact Timothy Lewis via email at

February 2018